KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Current Deferred Revenue (2023)

Biocryst Pharmaceuticals (BCRX) has disclosed Current Deferred Revenue for 7 consecutive years, with $522000.0 as the latest value for Q3 2023.

  • For the quarter ending Q3 2023, Current Deferred Revenue changed N/A year-over-year to $522000.0, compared with a TTM value of $522000.0 through Sep 2023, changed N/A, and an annual FY2014 reading of $5.6 million, up 280.52% over the prior year.
  • Current Deferred Revenue was $522000.0 for Q3 2023 at Biocryst Pharmaceuticals, down from $1.8 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $1.8 million in Q2 2023 and bottomed at $522000.0 in Q3 2023.